Conatus Pharmaceuticals Inc 4
4 · Conatus Pharmaceuticals Inc · Filed Aug 1, 2013
Insider Transaction Report
Form 4
Cashion Charles
SVP, Finance, CFO and Sec.
Transactions
- Conversion
Common Stock
2013-07-30+43,072→ 149,738 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2013-07-30−355,352→ 0 total(indirect: See footnote)→ Common Stock (43,072 underlying)
Footnotes (2)
- [F1]The outstanding shares of Preferred Stock of the Issuer automatically converted into the shares of Common Stock of the Issuer at the closing of the Issuer's initial public offering at a conversion ratio of 1 share of Common Stock for every 8.25 shares of Preferred Stock, rounded down to the nearest whole number, for no additional consideration.
- [F2]Held in a trust of which Mr. Cashion is a trustee.